This study aimed to compare the change in levels of several laboratory values and the development of adverse events using two commonly used intramuscular testosterone therapy regimens. Men were included if they were 18 years or older and received one of the following testosterone therapy regimens: 100 mg intramuscular once weekly or 200 mg intramuscular once every other week. Primary outcomes were relative changes in total testosterone, free testosterone, estradiol, prostate-specific antigen, and hematocrit at 6 months after initiation of testosterone therapy. Secondary outcomes were any significant rises in estradiol, hematocrit, prostate-specific antigen, and any other treatment-related adverse events requiring cessation of testosterone therapy. A total of 263 men were enrolled. In a subanalysis of men who had a baseline hematocrit below 54% before intramuscular testosterone therapy initiation, we found the following: men who received 100 mg weekly injections were significantly less likely to have hematocrit levels rising above 54% (1/102 (1%) vs. 4/51 (8%); p = 0.023). No significant differences were recorded in the increase in total testosterone, free testosterone, prostate-specific antigen, and estradiol levels between both groups. A higher average serum testosterone over the dosing interval seen with the 200 mg regimen appears to be associated with a higher risk of erythrocytosis.
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs. 2004;64:1861–91. https://doi.org/10.2165/00003495-200464170-00002
Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–76. https://doi.org/10.1210/er.2004-0013.
Zarotsky V, Huang M-Y, Carman W, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the epidemiology of nongenetic forms of hypogonadism in adult males. J Horm. 2014;2014:1–17.
Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol. 2006;65:275–81. https://doi.org/10.1111/j.1365-2265.2006.02618.x
Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Investig. 2008;31:718–23. https://doi.org/10.1007/BF03346421
Hudson’s guide: testosterone types and delivery. Hudson’s FTM Resource Guide. http://www.ftmguide.org/ttypes.html#bib.
Kang D-Y, Li H-J. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis: a systematic review and meta-analysis. Medicine. 2015;94:e410.
Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3:101–12.
Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, Serrano V, Singh-Ospina N, Rodriguez-Gutierrez R, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00404.
Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6:77–85. https://doi.org/10.1016/j.sxmr.2017.04.001
Griesshammer M, Kiladjian J-J, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071–82.
Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10:359–71.
Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol. 1991;146:1566–70. https://doi.org/10.1016/s0022-5347(17)38168-5
Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51. https://doi.org/10.1517/14740338.2014.950653
Nelson WG. Commentary on Huggins and Hodges: “studies on prostatic cancer. Cancer Res. 2016;76:186–7.
Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115–23. https://doi.org/10.1016/j.eururo.2013.08.015
Boyle P, Koechlin A, Bota M, d’Onofrio A, Zaridze DG, Perrin P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731–41. https://doi.org/10.1111/bju.13417
Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf. 2008;7:691–702. https://doi.org/10.1517/14740330802442382
Tan RS, Cook KR, Reilly WG. High estrogen in men after injectable testosterone therapy: the low T experience. Am J Mens Health. 2015;9:229–34. https://doi.org/10.1177/1557988314539000
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
El-Khatib, F.M., Huynh, L.M., Kopelevich, A. et al. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly. Int J Impot Res (2021). https://doi.org/10.1038/s41443-021-00449-0